for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zoetis Inc

ZTS.N

Latest Trade

136.31USD

Change

-2.03(-1.47%)

Volume

685,455

Today's Range

136.15

 - 

139.62

52 Week Range

82.80

 - 

143.32

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Zoetis Declares First Quarter 2020 Dividend Board Approves 22% Payment Increase

Dec 11 (Reuters) - Zoetis Inc <ZTS.N>::ZOETIS DECLARES FIRST QUARTER 2020 DIVIDEND; BOARD APPROVES 22% PAYMENT INCREASE.ZOETIS INC - BOARD HAS DECLARED A Q1 2020 DIVIDEND PAYABLE TO HOLDERS OF COMPANY'S COMMON STOCK OF $0.20 PER SHARE.

Zoetis Acquires Znlabs To Strengthen Its Comprehensive Diagnostics Portfolio

Nov 22 (Reuters) - Zoetis Inc <ZTS.N>::ZOETIS ACQUIRES ZNLABS, A NATIONWIDE VETERINARY REFERENCE LABORATORY, TO FURTHER STRENGTHEN ITS COMPREHENSIVE DIAGNOSTICS PORTFOLIO.ZOETIS INC - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED.

Zoetis Says CVMP Adopted By Consensus Positive Opinions For Renewal Of Marketing Authorisations For Coliprotec F4 And Zulvac SBV

Nov 8 (Reuters) - Zoetis Inc <ZTS.N>::CVMP ADOPTED BY CONSENSUS POSITIVE OPINIONS FOR RENEWAL OF MARKETING AUTHORISATIONS FOR COLIPROTEC F4 AND ZULVAC SBV.CVMP STARTED A PROCEDURE FOR SUVAXYN PRRS MLV (PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS VACCINE (LIVE)) FROM ZOETIS.

Zoetis Q3 Adjusted Earnings Per Share $0.94

Nov 7 (Reuters) - Zoetis Inc <ZTS.N>::ZOETIS ANNOUNCES THIRD QUARTER 2019 RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.94.Q3 EARNINGS PER SHARE $0.90.Q3 REVENUE $1.6 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.58 BILLION.SEES FY 2019 EARNINGS PER SHARE $2.99 TO $3.08.SEES FY 2019 REVENUE $6.2 BILLION TO $6.25 BILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.57 TO $3.62.Q3 EARNINGS PER SHARE ESTIMATE $0.88 -- REFINITIV IBES DATA.

Zoetis Sets Quarterly Dividend Of $0.164 Per Share

Oct 3 (Reuters) - Zoetis Inc <ZTS.N>::SETS QUARTERLY DIVIDEND OF $0.164PER SHARE.

Zoetis Names Kristin Peck To Succeed Juan Ramón Alaix As CEO On Jan. 1, 2020

Oct 3 (Reuters) - Zoetis Inc <ZTS.N>::ZOETIS NAMES KRISTIN PECK TO SUCCEED JUAN RAMÓN ALAIX AS CEO ON JANUARY 1, 2020.ZOETIS INC - ALAIX TO RETIRE AS CEO EFFECTIVE DECEMBER 31, 2019.ZOETIS INC - ALAIX WILL ACT AS ADVISOR ON LEADERSHIP TRANSITION THROUGH DECEMBER 31, 2020.ZOETIS INC - KRISTIN PECK WILL SUCCEED JUAN RAMÓN ALAIX AS CHIEF EXECUTIVE OFFICER OF ZOETIS, EFFECTIVE JANUARY 1.ZOETIS INC - PECK JOIN BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY.

Zoetis Announces Second Quarter 2019 Results

Aug 6 (Reuters) - Zoetis Inc <ZTS.N>::ZOETIS ANNOUNCES SECOND QUARTER 2019 RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.90.Q2 REVENUE $1.5 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.52 BILLION.SEES FY 2019 EARNINGS PER SHARE $2.93 TO $3.04.Q2 EARNINGS PER SHARE $0.77.SEES FY 2019 REVENUE $6.175 BILLION TO $6.275 BILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.53 TO $3.60.Q2 EARNINGS PER SHARE ESTIMATE $0.82 -- REFINITIV IBES DATA.

Zoetis Announces Acquisition Of Platinum Performance

July 22 (Reuters) - Zoetis Inc <ZTS.N>::ZOETIS ANNOUNCES THE ACQUISITION OF PLATINUM PERFORMANCE, A LEADING NUTRITION-FOCUSED ANIMAL HEALTH BUSINESS FOR EQUINE AND PETCARE MARKETS.ZOETIS INC - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED..ZOETIS INC - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED..ZOETIS INC - DOES NOT EXPECT TRANSACTION TO HAVE A MATERIAL FINANCIAL IMPACT TO ITS GUIDANCE FOR FULL-YEAR 2019..

Zoetis Q1 Adjusted Earnings Per Share $0.88

Zoetis Inc <ZTS.N>::UPDATES FULL YEAR 2019 REVENUE GUIDANCE TO $6.100 - $6.225 BILLION.ZOETIS ANNOUNCES FIRST QUARTER 2019 RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.88.Q1 EARNINGS PER SHARE $0.65.Q1 REVENUE $1.5 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.45 BILLION.SEES FY 2019 EARNINGS PER SHARE $2.79 TO $2.93.SEES FY 2019 REVENUE $6.1 BILLION TO $6.225 BILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $3.42 TO $3.52.Q1 EARNINGS PER SHARE ESTIMATE $0.79 -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $3.47, REVENUE VIEW $6.26 BILLION -- REFINITIV IBES DATA.

EMA Says CVMP Adopted By Consensus Positive Opinion For Grouped Type II Variation Application For Suvaxyn PRRS MLV

April 23 (Reuters) - EMA::CVMP ADOPTED BY CONSENSUS A POSITIVE OPINION FOR A GROUPED TYPE II VARIATION APPLICATION FOR SUVAXYN PRRS MLV.ADOPTED BY CONSENSUS A POSITIVE OPINION FOR THE RENEWAL OF THE MARKETING AUTHORISATION FOR OSURNIA.CVMP ALSO REVIEWED THE PSUR FOR CYTOPOINT AND RECOMMENDED AMENDMENTS TO THE PRODUCT INFORMATION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up